BackgroundCheck.run
Search For

Carlos A Zarate, 661057 Quiet Waters Ln, Lawrenceville, GA 30045

Carlos Zarate Phones & Addresses

1057 Quiet Waters Ln, Lawrenceville, GA 30045    770-9620458   

3531 98Th St, Corona, NY 11368   

9201 Lamont Ave, Elmhurst, NY 11373    718-4580596   

8337 Saint James Ave, Elmhurst, NY 11373    718-4583261   

Middle Village, NY   

Dacula, GA   

Jamaica, NY   

Work

Company: Jetblue airways Apr 2012 Position: Material specialist

Education

School / High School: Farmingdale State University of New York- Farmingdale, NY Jun 2001 Specialities: Associate in Arts in Liberal Arts & Sciences

Skills

ADP Software • Mac OS platform • MS Package • Macknet • Compass • Paccar • Extranet • Trax

Mentions for Carlos A Zarate

Career records & work history

License Records

Carlos A Zarate

Licenses:
License #: E121808 - Active
Category: Emergency medical services
Issued Date: May 18, 2016
Expiration Date: May 31, 2018
Type: San Francisco EMS Agency

Carlos Zarate resumes & CV records

Resumes

Carlos Zarate Photo 47

Carlos Zarate

Carlos Zarate Photo 48

Carlos Zarate

Carlos Zarate Photo 49

Carlos Zarate

Skills:
Treatment
Carlos Zarate Photo 50

Carlos Zarate

Carlos Zarate Photo 51

Carlos Zarate

Carlos Zarate Photo 52

Carlos Zarate

Carlos Zarate Photo 53

Carlos Zarate

Carlos Zarate Photo 54

Carlos Zarate

Publications & IP owners

Us Patents

Intranasal Administration Of Ketamine To Treat Depression

US Patent:
2007028, Dec 13, 2007
Filed:
Mar 20, 2007
Appl. No.:
11/688603
Inventors:
Dennis Charney - Chappaqua NY, US
Sanjay Mathew - New York NY, US
Husseini Manji - Rockville MD, US
Carlos Zarate - Germantown MD, US
John Krystal - Woodbridge CT, US
Assignee:
MOUNT SINAI SCHOOL OF MEDICINE - New York NY
NATIONAL INSTITUTE OF HEALTH - Rockville MD
YALE UNIVERSITY SCHOOL OF MEDICINE - New Haven CT
International Classification:
A61K 31/135
A61K 33/14
A61K 36/00
A61M 11/00
A61M 5/00
A61P 25/24
US Classification:
514647000, 128200140, 424449000, 424722000, 424725000, 604046000
Abstract:
Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.